Comprehensive Analysis of Fraction of Genome Altered in Prostate Cancer Treatment
Open Access
- 1 September 2025
- journal article
- Published by Wiley in The Prostate
- Vol. 85 (16) , 1513-1521
Abstract
Background: Genomic instability is a key feature of cancer and plays a central role in tumor progression. One emerging metric for genomic instability is the fraction of genome altered (FGA), which quantifies the proportion of the genome affected by copy number alterations. Previous studies in various solid tumors have shown that high FGA is associated with aggressive disease and adverse clinical outcomes. However, the clinical significance of FGA in prostate cancer (PC) remains unclear. In this study, we investigated the role of FGA as a potential biomarker of tumor aggressiveness and a poor prognosis in PC using several large‐scale public databases. Methods: We analyzed the processed data from previous large‐scale PC studies available through the cBioPortal database: MSK CHORD 2024 ( n = 3211), MSK 2021 ( n = 2069), MSK 2020 mCSPC ( n = 424), SU2C/PCF mCRPC ( n = 444), and AACR Project GENIE ( n = 5306). Associations between FGA and clinical parameters such as T stage, Gleason score (GS), tumor volume, metastatic burden, pathological subtype, and treatment history were evaluated. Kaplan–Meier survival analysis was used to assess the prognostic value of FGA. Results: High FGA was significantly associated with aggressive clinical features, including higher T stage, GS, metastatic burden, and neuroendocrine prostate cancer histology. FGA increased after most therapeutic interventions. Patients with high FGA had significantly poorer overall survival across nearly all treatment modalities. An oncoplot analysis revealed a higher frequency of somatic alterations in key driver genes, including AR, PTEN , and TP53 , in high‐FGA tumors. Conclusions: FGA was closely associated with tumor aggressiveness, therapy‐induced genomic instability, and a poor prognosis in PC. It may serve as a clinically relevant biomarker across diverse treatment contexts.Keywords
This publication has 27 references indexed in Scilit:
- Automated real-world data integration improves cancer outcome predictionNature, 2024
- Association between copy number alterations estimated using low-pass whole genome sequencing of formalin-fixed paraffin-embedded prostate tumor tissue and cancer-specific clinical parametersScientific Reports, 2023
- Tumor aneuploidy predicts survival following immunotherapy across multiple cancersNature Genetics, 2022
- Machine learning of genomic features in organotropic metastases stratifies progression risk of primary tumorsNature Communications, 2021
- Prostate cancer liver metastasis: Dormancy and resistance to therapySeminars in Cancer Biology, 2021
- Androgen receptor enhancer amplification in matched patient‐derived xenografts of primary and castrate‐resistant prostate cancerThe Journal of Pathology, 2021
- Clinical and Biological Features of Neuroendocrine Prostate CancerCurrent Oncology Reports, 2021
- The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung AdenocarcinomaJournal of Thoracic Oncology, 2020
- Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancerThe Prostate, 2015
- The Molecular Taxonomy of Primary Prostate CancerCell, 2015